Moderna's stock pops after biotech ekes out profit and revenue beats by a wide marginMarket Watch • 11/07/24
Moderna Posts A Surprise Profit As Sales Wallop Views. But Will RSV Be Its Undoing?Investors Business Daily • 11/07/24
Moderna Reports Third Quarter 2024 Financial Results and Provides Business UpdatesAccesswire • 11/07/24
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?Zacks Investment Research • 11/05/24
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024PRNewsWire • 11/05/24
Moderna (MRNA) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance MeasuresZacks Investment Research • 11/04/24
Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/31/24
mRNA Synthesis & Manufacturing Market to Hit USD 2958.3 million by 2029 with 5.8% CAGR | MarketsandMarkets™GlobeNewsWire • 10/29/24
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)Business Wire • 10/28/24